A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.

Bernhard J. Eigl,Eric Winquist,Dongsheng Tu,Sebastien J. Hotte,Christina M. Canil,Richard Gregg,Muhammad Zulfiqar,Scott North,Susan Ellard,Joseph D. Ruether,Lyly Le,Ankineedu Saranya Kakumanu,Ashley Theis,Christopher M. Booth,Kylea Potvin,Kim N. Chi,Lesley Seymour

A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.

2017

Bernhard J. Eigl
Eric Winquist
Dongsheng Tu
Sebastien J. Hotte
Christina M. Canil
Richard Gregg
Muhammad Zulfiqar
Scott North
Susan Ellard
Joseph D. Ruether
Lyly Le
Ankineedu Saranya Kakumanu
Ashley Theis
Christopher M. Booth
Kylea Potvin
Kim N. Chi
Lesley Seymour

5021Background: Pelareorep (REO) is an oncolytic virus with in vitro and in vivo activity in many cancers, including prostate. It has in vitro synergism with microtubule targeted agents especially ...

Keywords:

Cancer
Physical therapy
Prostate cancer
Phases of clinical research
Cancer research
Castration
Medicine
Docetaxel
in patient
Oncology
In vivo
Oncolytic virus
Internal medicine
Prostate
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations